We back great science and enable novel solutions

Accelerator Life Science Partners (ALSP) is a US and Singapore-based early-stage life science accelerator and investment firm that creates and builds biotech companies based on innovative science.

The company catalyses the development and commercialisation of breakthrough biotech innovations by providing a holistic toolkit and leveraging its network and entrepreneurial expertise to accelerate the establishment and operation of early-stage biotech companies.

Allay Therapeutics is a US and Singapore-based biotech company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians.

The company’s proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates which provide pain relief within a targeted site over weeks.

Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation.

Automera aims to leverage its unique understanding of autophagy, drug development capabilities, and access to quantum chemistry and generative AI-enabled insights to enhance its drug development programs. Automera’s AUTAC platform has broad potential across cancer and other disease areas, with oncology being the initial lead program.

The company was founded by co-founders Associate Professor Michael Lazarou, Loong Wang and Taiyang Zhang at Talo Labs Pte Ltd.

CoVBio is developing booster vaccines and therapeutics that are effective against variants of SARS-2 beta coronavirus.

The company’s booster pan-sarbecovirus vaccine will protect against future variants and future crossovers of related coronaviruses from animals to humans.

Engine Biosciences is a Singapore and US-based company that develops precision medicine-based therapies for cancer and other diseases, using machine learning and large-scale experimental biological data generation and testing to decipher complex genetic networks.

The company’s proprietary technology platforms seek to integrate vast and differentiated human and disease datasets, machine learning, combinatorial genetics experiments, and in-house drug discovery to identify and develop promising drug targets for specific patient genetic and treatment contexts. Engine Biosciences’ technologies enable researchers and drug developers to feed and advance their therapeutics pipelines to treat unmet medical needs across a range of diseases.

Hummingbird Bioscience is a data-driven multidisciplinary team discovering and developing transformative precision biotherapeutics for hard-to-treat diseases. Leveraging computational and systems biology, the company’s proprietary approach has yielded wholly owned clinical-stage drug candidates now in development.

Lightstone Ventures is a global venture capital firm investing in early stage, therapeutic-oriented companies across the life science spectrum, as well as opportunistic late-stage companies.

Operating in Menlo Park, Boston, Ireland and Singapore, the company aims to empower founders to bring innovative therapeutics to patients.

MediSix Therapeutics is a Singapore-based immune engineering company that develops novel cellular therapies to address T-cell malignancies and autoimmune diseases.

The company has developed a technology platform on genetic engineering that utilises proprietary immune engineering approaches to generate T-cells for effective immune cell therapies.

Founded with a focus on supporting biotech innovation, NSG BioLabs offers state-of-the-art equipment, efficient operations, capital efficiency, the expertise of world-class teams and global networks to assist life sciences companies. The conducive R&D environment contains fully-equipped, certified BSL-2 laboratory and office infrastructure across 35,000 sq ft in the prime location of Biopolis in Singapore.

By providing access to high-quality infrastructure, its extensive partner network, community, and value-add benefits, NSG BioLabs ensures that companies, ranging from emerging biotech startups to multinational companies, can rapidly and efficiently execute on their cutting-edge research and development ecosystem in Singapore, leading to the innovation of revolutionary technologies and products that translate into breakthrough biotech ventures and impact for patients.

Nuevocor is a Singapore-based biotech company developing targeted gene therapies to restore heart function through a deep understanding of fundamental mechanisms underlying genetic cardiac diseases.

The company is founded and advised by leaders in mechanobiology, cardiac disease and gene therapy. Its lead candidate treats the underlying biomechanical cause of LMNA dilated cardiomyopathy, while its PrOSIA mechanobiology platform enables target discovery and validation for additional genetic cardiomyopathies.

One BioMed is revolutionizing health research and testing. The company's innovative Xceler8™ Solution offers fully automated, affordable and rapid nucleic acid extraction and purification from a wide array of biological samples for research and clinical applications. This disruptive platform, underpinned by a novel chemistry-based approach, enables high quality extraction of ultra-high molecular weight DNA, DNA and RNA for long and short read sequencing.

Paratus Sciences is committed to improving human health and health security by understanding the exceptional biology of bats. The company is focused on identifying and developing human therapeutics for diseases of high unmet need, including inflammation, virology, metabolism, oncology, and autoimmune disorders.

Polaris Partners aims to accelerate the commercial and therapeutic potential of disruptive healthcare and technology companies across the innovation cycle. By partnering with passionate entrepreneurs with transformational science, Polaris’ Fund fosters creation and growth of companies through an active investment model.

Quilt is a generative AI-powered platform to create and discover fast-acting, personalized interventions to support individuals during moments of stress, anxiety, insomnia, low mood, and other challenges they may face. Through its mobile-based digital biomarkers, Quilt also identifies and connects at-risk individuals to relevant care services and products.

Sunbird Bio is developing protein-based diagnostic tests that provide unprecedented insights to enable earlier, more accurate diagnosis and treatment of Alzheimer’s disease, other neurological disorders and early-stage cancer.

The company's APEX technology is the first test that has demonstrated ability to detect – with a simple blood draw – low levels of the aggregated amyloid beta (Aβ) proteins that signal the presence of Alzheimer’s disease. APEX has significant promise for use in other neurological disorders as well. Its pipeline of innovative, non-invasive technologies will empower researchers and clinicians with unparalleled insights not available from current tests.

Virtual Therapeutics is a digital health company delivering scalable, accessible, and affordable personalized solutions for mental health and mental fitness. The company leverages its expertise in game development to create engaging experiences that integrate proven therapeutic techniques with modern gameplay elements. Its powerful cloud-based platform collects and analyzes data to continuously measure, validate and report effectiveness. This enables Virtual Therapeutics to seamlessly deploy and maintain its solutions, providing users and partners with a comprehensive, turnkey experience.